Biomarkers studied >2 times
Author | Biomarker | Total n | Sensitivity | Specificity | PPV | NPV | LR+ | LR− |
Blaschke et al11 | Anti-CCP+ | 50 | 0.65 | 0.68 | 0.77 | 0.54 | 2.04 | 0.5 |
Choi et al12 | Anti-CCP+ | 146 | 0.74 | 0.44 | 0.80 | 0.36 | 1.33 | 0.6 |
Klaasen et al13 | Anti-CCP+ | 101 | 0.71 | 0.56 | 0.78 | 0.47 | 1.62 | 0.5 |
Lequerré et al16 | Anti-CCP+ | 76 | 0.66 | 0.24 | 0.58 | 0.30 | 0.87 | 1.4 |
Matsudaira et al17 | Anti-CCP+ | 188 | 0.89 | 0.05 | 0.78 | 0.11 | 0.94 | 2.1 |
Pers et al14 | Anti-CCP+ | 56 | 0.76 | 0.33 | 0.76 | 0.33 | 1.13 | 0.7 |
Wampler Muskardin et al15 | Anti-CCP+ | 92 | 0.65 | 0.36 | 0.53 | 0.48 | 1.01 | 1.0 |
Zhao et al18 | Anti-CCP+ | 60 | 0.86 | 0.00 | 0.83 | 0.00 | 0.86 | ∞ |
Abhishek et al20 | RF+ | 279 | 0.74 | 0.20 | 0.89 | 0.09 | 0.93 | 1.3 |
Blaschke et al11 | RF+ | 50 | 0.55 | 0.68 | 0.74 | 0.71 | 1.74 | 0.7 |
Choi et al12 | RF+ | 146 | 0.68 | 0.53 | 0.82 | 0.35 | 1.44 | 0.6 |
Hyrich et al22 | RF+ | 2879 | 0.72 | 0.29 | 0.76 | 0.25 | 1.02 | 1.0 |
Klaasen et al13 | RF+ | 101 | 0.71 | 0.56 | 0.78 | 0.47 | 1.62 | 0.5 |
Lequerré et al16 | RF+ | 76 | 0.53 | 0.41 | 0.60 | 0.35 | 0.91 | 1.1 |
Morales-Lara et al21 | RF+ | 89 | 0.88 | 0.12 | 0.63 | 0.36 | 1.00 | 1.0 |
Salgado et al19 | RF+ | 374 | 0.71 | 0.23 | 0.80 | 0.16 | 0.92 | 1.3 |
Zhao et al18 | RF+ | 60 | 0.59 | 0.22 | 0.81 | 0.09 | 0.76 | 1.9 |
Cuchacovich et al28 | TNF-α (−308) GG genotype | 70 | 0.78 | 0.50 | 0.88 | 0.32 | 1.55 | 0.4 |
Guis et al23 | TNF-α (−308) GG genotype | 86 | 0.85 | 0.40 | 0.82 | 0.44 | 1.41 | 0.4 |
Jančić et al27 | TNF-α (−308) GG genotype | 73 | 0.89 | 0.18 | 0.86 | 0.22 | 1.08 | 0.6 |
Marotte et al24 | TNF-α (−308) GG genotype | 198 | 0.76 | 0.28 | 0.67 | 0.37 | 1.05 | 0.9 |
Miceli-Richard et al29 | TNF-α (−308) GG genotype | 369 | 0.67 | 0.26 | 0.38 | 0.54 | 0.91 | 1.3 |
Mugnier et al25 | TNF-α (−308) GG genotype | 53 | 0.87 | 0.47 | 0.80 | 0.58 | 1.63 | 0.3 |
Padyukov et al26 | TNF-α (−308) GG genotype | 123 | 0.66 | 0.50 | 0.84 | 0.26 | 1.31 | 0.7 |
Kang et al30 | HLA-DRB1 ≥1 SE copies | 66 | 0.72 | 0.22 | 0.85 | 0.11 | 0.92 | 1.3 |
Marotte et al24 | HLA-DRB1 ≥1 SE copies | 198 | 0.72 | 0.30 | 0.67 | 0.35 | 1.02 | 0.9 |
Miceli-Richard et al29 | HLA-DRB1 ≥1 SE copies | 322 | 0.78 | 0.28 | 0.43 | 0.66 | 1.09 | 0.8 |
Skapenko et al31 | HLA-DRB1 ≥1 SE copies | 443 | 0.73 | 0.38 | 0.49 | 0.63 | 1.17 | 0.7 |
Avila-Pedretti et al34 | FcGR2A RR genotype | 299 | 0.80 | 0.21 | 0.88 | 0.14 | 1.02 | 0.9 |
Davila-Fajardo et al32 | FcGR2A RR genotype | 302 | 0.65 | 0.24 | 0.50 | 0.38 | 0.86 | 1.4 |
Cañete et al33 | FcGR2A RR genotype | 85 | 0.69 | 0.15 | 0.56 | 0.24 | 0.82 | 2.0 |
Values are unadjusted.
CCP, cyclic citrullinated peptide; LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; RF, rheumatoid factor.